Case Studies

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A well-capitalized cancer immunotherapy company, operating in a highly competitive field, needed to benchmark its financial status and staff numbers against its peers to help gauge its...

Challenge A European Biotech company with its lead product being developed for a rare oncology disease in Phase 1 wanted to understand how to optimize and evaluate the commercial potential of the...

Challenge A research-based biotech needed a clear understanding of the processes, resources and timelines to establish a global pharma supply chain for their leading pipeline compound, a therapy for...

Challenge A late stage biotech needed a clear understanding of the processes, resource needs and timelines to establish global commercial operations to launch their leading pipeline compound, a...

Challenge A small, Swiss-based biotechnology company with a pre-commercial pipeline of therapeutic antibodies for rare and ultra-rare diseases was preparing to launch its first asset. This company...

Challenge A new academic spin-out company in Europe had acquired the rights to the intellectual property covering a new diagnostic agent. This molecular MRI imaging tool is envisioned to be useful in...

Challenge Dual-energy X-ray absorptiometry (DXA) has been used extensively in clinical trials in osteoporosis. DXA is increasingly being used to examine bone density in trials of drugs that could...

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...

Challenge A private biotech company was preparing for an IPO. The company was developing a first-in-class small molecule inhibitor with the potential to treat a range of tumor types. The company was...

Challenge A start-up biotechnology company was developing a new oncology therapeutic for the treatment of advanced solid tumors. The product consists of four FDA-approved and well-tolerated...

Challenge A US biotech company had a small molecule anti-cancer drug on the market in the US and other products in development. The company needed CMC consulting expertise in order to access European...